Osteopore Ltd. (OSX) AI Stock Analysis

• Market Cap: AU$1.91M
• Dividend Yield: N/A
• Average Volume (3M): 2.16M
• Price to Earnings (P/E): ―
• Beta (1Y): 4.50
• Revenue Growth: 5.52%
• EPS Growth: 49.25%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): >-0.01
• Shares Outstanding: 272,501,800
• 10 Day Avg. Volume: 675,672
• 30 Day Avg. Volume: 2,156,422
• PEG Ratio: 0.02
• Price to Book (P/B): 8.95
• Price to Sales (P/S): 0.97
• P/FCF Ratio: -0.88
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: AU$0.01 ▲(10.00% Upside)

Osteopore Ltd. faces significant challenges with profitability and cash flow, heavily impacting its financial performance score. Technical indicators show a lack of momentum, and valuation metrics are unfavorable due to negative earnings. These factors collectively result in a low overall stock score.

Positive Factors

Revenue Growth

The company's ability to achieve consistent revenue growth indicates strong market demand and effective sales strategies, which are crucial for long-term sustainability and expansion in the medical device sector.

Product Innovation

Osteopore's focus on innovative, biodegradable implants and scaffolds positions it well in the medical device industry, offering a competitive advantage through advanced biomaterials that promote natural bone growth.

Gross Profit Margin

A high gross profit margin reflects efficient production and pricing strategies, allowing Osteopore to maintain profitability potential despite current operational challenges.

Negative Factors

Profitability Challenges

Persistent negative profit margins highlight operational inefficiencies and high costs, which could hinder long-term financial health if not addressed.

High Leverage

High leverage increases financial risk and limits flexibility, potentially impacting Osteopore's ability to invest in growth opportunities or weather economic downturns.

Cash Flow Challenges

Negative cash flows indicate inefficiencies in converting revenue into cash, which could strain operations and necessitate reliance on external financing, posing risks if funding becomes constrained.

Osteopore Ltd. Business Overview & Revenue Model

Company Description

Osteopore Ltd. (OSX) is a biotechnology company specializing in the development of innovative, biodegradable implants and scaffolds for bone regeneration. Focused primarily on the medical device sector, Osteopore utilizes its proprietary technology to create products designed to facilitate the healing of bone fractures and defects. The company aims to enhance patient outcomes through its advanced biomaterials that promote natural bone growth, with applications across various medical fields, including orthopedics, craniofacial surgery, and dental implants.

How the Company Makes Money

Osteopore generates revenue primarily through the sale of its biodegradable implants and scaffolds to hospitals, clinics, and medical practitioners. The company's revenue model includes direct sales of its products, which are often covered by health insurance plans, allowing for wider adoption among healthcare providers. Additionally, Osteopore may engage in strategic partnerships with medical device distributors and healthcare organizations to expand its market reach. The company also invests in research and development to innovate and improve its offerings, which can lead to licensing agreements or collaborations that further contribute to its revenue streams.

Osteopore Ltd. Financial Statement Overview

Summary

Osteopore Ltd. shows revenue growth but faces significant profitability and cash flow challenges. The company has high leverage and relies on external financing, increasing financial risk. Persistent losses and negative cash flows are major concerns.

Income Statement

Osteopore Ltd. shows consistent revenue growth, with a 26.82% increase in 2024. However, the company is struggling with profitability, as evidenced by negative net profit margins and EBIT margins over the years. The gross profit margin remained healthy at over 84% in 2024, but the persistent negative EBIT and net income indicate significant operational challenges and high costs relative to revenue.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio, with total debt surpassing equity in 2024, increasing financial risk. The equity ratio decreased significantly, indicating a shift towards higher leverage. ROE is negative due to ongoing losses, raising concerns over shareholder returns. However, the company maintains some cash reserves, which may provide short-term liquidity.

Cash Flow

Osteopore Ltd. faces cash flow challenges, with negative operating and free cash flows throughout the periods. The free cash flow growth rate is negative, highlighting ongoing cash burn. The operating cash flow to net income ratio remains unfavorable, reflecting inefficiencies in converting revenue into cash. The firm is reliant on financing activities to sustain operations, which could pose risks if funding sources become limited.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.89M	2.81M	2.22M	1.69M	1.11M	1.50M
Gross Profit	2.30M	2.37M	1.64M	1.27M	811.64K	955.33K
EBITDA	-2.42M	-2.34M	-4.35M	-3.97M	-3.38M	-1.76M
Net Income	-3.26M	-3.35M	-4.87M	-4.22M	-3.62M	-1.95M
Balance Sheet
Total Assets	4.19M	3.13M	3.34M	3.62M	6.01M	10.25M
Cash, Cash Equivalents and Short-Term Investments	1.81M	638.50K	1.16M	1.35M	4.55M	9.03M
Total Debt	1.68M	1.33M	1.09M	74.18K	106.71K	453.99K
Total Liabilities	4.62M	2.83M	2.91M	1.51M	633.40K	1.25M
Stockholders Equity	-423.65K	306.22K	432.60K	2.11M	5.37M	9.00M
Cash Flow
Free Cash Flow	-2.71M	-3.10M	-3.74M	-4.06M	-4.00M	-2.14M
Operating Cash Flow	-2.69M	-3.09M	-3.74M	-4.00M	-3.81M	-1.76M
Investing Cash Flow	-17.19K	-14.59K	-7.37K	-63.98K	-194.62K	-381.04K
Financing Cash Flow	2.58M	2.63M	3.58M	896.32K	-485.88K	7.84M

Osteopore Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IME	59 Neutral	AU$17.79M	-3.84	-27.84%	―	6.77%	-8.45%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ARX	49 Neutral	AU$219.10M	-135.42	-2.01%	―	16.93%	76.47%
OSX	41 Neutral	AU$1.91M	-0.46	-487.52%	―	5.52%	49.25%
OCC	41 Neutral	AU$277.87M	-28.13	-89.70%	―	42.05%	-0.84%
EMD	41 Neutral	AU$42.62M	-7.43	-81.30%	―	-36.68%	79.41%
ALA	40 Underperform	AU$98.50M	-11.47	-47.98%	―	700.00%	26.88%

Osteopore Ltd. Corporate Events

Osteopore Ltd. Issues New Convertible Notes to Bolster Growth

Osteopore Ltd. announced the issuance of new unquoted convertible notes, marking a strategic financial move to support its ongoing operations and growth initiatives. This development could enhance the company’s financial flexibility, potentially impacting its market positioning and offering new opportunities for stakeholders.

Osteopore Ltd. Advances Funding with Convertible Notes Issuance

Osteopore Ltd. has issued a Cleansing Notice related to the issuance of convertible notes under a subscription agreement with Advance Opportunities Fund. This agreement allows the company to raise up to $20 million through redeemable convertible notes, with the latest tranche amounting to $250,000. The issuance of these notes enables the company to convert them into fully paid ordinary shares, which can be sold to retail investors without further disclosure. This financial maneuver is significant for Osteopore as it provides additional capital to support its operations and potentially strengthens its market position in the medical technology sector.

Osteopore Secures Additional Funding to Advance Regenerative Medicine Solutions

Osteopore Limited has announced a further drawdown of its Tranche 1 redeemable convertible notes, raising an additional A$250,000. This funding, part of a larger A$20 million subscription agreement with Advance Opportunities Fund, will support the company’s ongoing business operations and future development projects. The strategic financial move is expected to bolster Osteopore’s market positioning and facilitate the advancement of its innovative regenerative medicine solutions.

Osteopore Ltd. Expands Market Presence with New Securities Quotation

Osteopore Ltd. has announced the quotation of 18,292,682 new ordinary fully paid securities on the Australian Securities Exchange (ASX), effective November 19, 2025. This move is part of the company’s strategic efforts to enhance its market presence and operational capabilities, potentially impacting its financial standing and offering new opportunities for stakeholders.

Osteopore Ltd. Announces Change in Substantial Holding

Osteopore Ltd. has announced that Advance Opportunities Fund I has ceased to be a substantial holder in the company. This change in holdings, involving the indirect sale of shares, may impact the company’s market dynamics and influence stakeholder perceptions regarding the company’s financial stability and investor confidence.

Osteopore Ltd. Announces Cessation of Securities

Osteopore Ltd. announced the cessation of 12,500 securities due to the lapse of conditional rights, as the conditions for these securities were not met by the expiration date. This cessation may impact the company’s capital structure and could influence investor perception, reflecting on the company’s ability to meet certain financial or operational conditions.

Osteopore Reports Revenue Growth and Swiss Market Approval

Osteopore Limited reported a revenue of AUD 812K for the third quarter of 2025, marking a 7% year-over-year growth. The company also achieved a significant milestone by securing market approval in Switzerland under the EU MDR clearance for its custom orthopedic and cranial implants, potentially enhancing its market presence in Europe.

Osteopore Partners with Tan Tock Seng Hospital for AVN Implant Development

Osteopore Limited has announced a collaboration with Tan Tock Seng Hospital to develop a novel implant for treating avascular necrosis (AVN) at the hip joint. This partnership, funded by a SGD 50,000 MedTech grant from NHG Health, aims to enhance outcomes for core decompression in AVN and could potentially reduce healthcare costs. The AVN treatment market is projected to grow significantly, reaching USD 10.2 billion by 2030, driven by increased awareness and earlier diagnosis.